Biotech Stock Could Double: Is This the Next Big Thing?
Imagine a stock that has plunged 70% in a year, yet an investment bank believes it could skyrocket by almost 100%. Goldman Sachs sees precisely this potential in Biohaven, a little-known biotech company. Their bold call hinges on Biohaven's promising kidney disease treatment, which could capture a massive market share. Furthermore, the company's epilepsy drug also shows significant promise, with crucial data expected soon. This under-the-radar play could be the next big thing, so subscribe now to stay ahead of the curve!
Tags/Hashtags: #biohaven #biotech #investing #epilepsy #healthcare #biohaven #bhvn #opakalim #azetukalner #xene
Leave a Reply